We are thrilled to announce our participation in the San Antonio Breast Cancer Symposium (SABCS) 2024, the world’s largest conference focused on breast cancer. Held annually in San Antonio, Texas, SABCS brings together over 12,000 leading oncologists, scientists, and experts to share breakthroughs and shape the future of breast cancer care.
As the final major oncology conference of the year, SABCS 2024 was a fitting conclusion to our busy and rewarding year. At the symposium, we presented a poster detailing our study on Multiplex8+, our spatially informed diagnostic test. The study demonstrated the test’s feasibility in real-world clinical settings, with a 91% alignment to traditional IHC methods and 93% overall accuracy.
Participating in SABCS allowed us to showcase our commitment to advancing breast cancer diagnostics and to connect with global leaders in the field. We’re proud to represent Slovak innovation on the world stage.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter